Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Chief Technical Ops. Officer | March 03, 2023 | March 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUTRO BIOPHARMA, INC.
Report date March 03, 2023 · Filed March 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,827 |
Ending reported balance
After 2023-03-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2023-03-03 · Exercise / conversion · Acquired 7,875 · Balance 38,299 F1: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Row 2 · 2023-03-03 · Exercise / conversion · Acquired 8,750 · Balance 47,049 F1: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Row 3 · 2023-03-03 · Tax withholding · Disposed 6,222 · Balance 40,827 F2: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2025-03-01 | Direct | 40,000 |
Reported balance
After 2023-03-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-03 · Grant · Acquired 40,000 · Balance 40,000 F1: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3: The RSUs vest as to 1/2 of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2026-03-04 | Direct | 23,625 |
Reported balance
After 2023-03-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-03 · Exercise / conversion · Disposed 7,875 · Balance 23,625 F1: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2025-03-05 | Direct | 17,500 |
Reported balance
After 2023-03-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-03 · Exercise / conversion · Disposed 8,750 · Balance 17,500 F1: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F2: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
F3: The RSUs vest as to 1/2 of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date.
F4: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date.
F5: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2023 Filed Mar 7, 2023 16:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016739 · doc4.xml · derivative · entry 6 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 8,750 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016739 · doc4.xml · derivative · entry 5 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,625 Underlying: Common Stock · 7,875 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016739 · doc4.xml · derivative · entry 4 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2025-03-01 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/2 of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 6,222 | $5.79 | $36,025.38 |
DisclosureSEC source: 0001209191-23-016739 · doc4.xml · nonDerivative · entry 3 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,827 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016739 · doc4.xml · nonDerivative · entry 2 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 7,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016739 · doc4.xml · nonDerivative · entry 1 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005754 · doc4.xml · derivative · entry 3 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 1,835 | $7.50 | $13,762.50 |
DisclosureSEC source: 0001209191-23-005754 · doc4.xml · nonDerivative · entry 2 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,424 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005754 · doc4.xml · nonDerivative · entry 1 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016850 · doc4.xml · derivative · entry 5 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 8,750 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,200 | $8.17 | $26,144.00 |
DisclosureSEC source: 0001209191-22-016850 · doc4.xml · nonDerivative · entry 2 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,759 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016850 · doc4.xml · nonDerivative · entry 1 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 19:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 31,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016850 · doc4.xml · derivative · entry 4 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2026-03-04 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 19:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 42,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001209191-22-016850 · doc4.xml · derivative · entry 3 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2032-03-03 F3 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 4, 2022, with 100% of the total shares vested and exercisable on March 4, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 20:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 1,844 | $10.39 | $19,159.16 |
DisclosureSEC source: 0001209191-22-006121 · doc4.xml · nonDerivative · entry 2 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,209 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 20:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006121 · doc4.xml · nonDerivative · entry 1 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:53 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057976 · doc4.xml · derivative · entry 3 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,609 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:53 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,976 | $19.23 | $57,228.48 |
DisclosureSEC source: 0001209191-21-057976 · doc4.xml · nonDerivative · entry 2 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,553 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:53 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057976 · doc4.xml · nonDerivative · entry 1 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 17:17 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018618 · doc4.xml · derivative · entry 2 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2025-03-05 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 17:17 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $21.11 | $0.00 |
DisclosureSEC source: 0001209191-21-018618 · doc4.xml · derivative · entry 1 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-03-04 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 5, 2021, with 100% of the total shares vested and exercisable on March 5, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 17:53 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006554 · doc4.xml · derivative · entry 3 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 4,500 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 17:53 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 1,845 | $22.15 | $40,866.75 |
DisclosureSEC source: 0001209191-21-006554 · doc4.xml · nonDerivative · entry 2 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,920 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 17:53 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006554 · doc4.xml · nonDerivative · entry 1 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2021 Filed Feb 1, 2022 20:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006121 · doc4.xml · derivative · entry 3 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 4,500 shares Expires 2025-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:53 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052244 · doc4.xml · derivative · entry 3 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,609 Underlying: Common Stock · 8,609 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:53 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,976 | $10.30 | $30,652.80 |
DisclosureSEC source: 0001209191-20-052244 · doc4.xml · nonDerivative · entry 2 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,265 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:53 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052244 · doc4.xml · nonDerivative · entry 1 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 17:15 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005806 · doc4.xml · derivative · entry 2 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2024-01-29 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 17:15 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 41,250 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001209191-20-005806 · doc4.xml · derivative · entry 1 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Stock · 41,250 shares Expires 2030-01-29 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 29, 2020, with 100% of the total shares vested and exercisable on January 29, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:19 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051117 · doc4.xml · derivative · entry 3 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,218 Underlying: Common Stock · 8,608 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:19 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,976 | $9.74 | $28,986.24 |
DisclosureSEC source: 0001209191-19-051117 · doc4.xml · nonDerivative · entry 2 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,632 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:19 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051117 · doc4.xml · nonDerivative · entry 1 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:07 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 35,000 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-19-006201 · doc4.xml · derivative · entry 1 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 17:49 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 25,826 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052477 · doc4.xml · derivative · entry 2 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,826 Underlying: Common Stock · 25,826 shares Expires 2021-09-25 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 17:49 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 154,958 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052477 · doc4.xml · derivative · entry 1 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,958 Underlying: Common Stock · 154,958 shares Expires 2028-09-25 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.